No relevant activity of olaratumab in patient-derived soft tissue sarcoma xenografts selected for expression of platelet-derived growth factor receptor a.

Jasmien Cornillie,Britt Van Renterghem,Nathalie Van Winkel,Jasmien Wellens,Yemarshet K. Gebreyohannes,Maria Debiec-Rychter,Raf Sciot,Daphne Hompes,Agnieszka Woźniak,Patrick Schöffski

No relevant activity of olaratumab in patient-derived soft tissue sarcoma xenografts selected for expression of platelet-derived growth factor receptor a.

2019

Jasmien Cornillie
Britt Van Renterghem
Nathalie Van Winkel
Jasmien Wellens
Yemarshet K. Gebreyohannes
Maria Debiec-Rychter
Raf Sciot
Daphne Hompes
Agnieszka Woźniak
Patrick Schöffski

e22556Background: Soft tissue sarcoma (STS) comprises a heterogeneous family of rare tumors of mesenchymal origin. Single-agent doxorubicin (DOX) remains the standard-of-care for advanced and inope...

Keywords:

Doxorubicin
Soft tissue sarcoma
Pathology
Mesenchymal stem cell
Olaratumab
Platelet-derived growth factor receptor
Medicine
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations